Currently, genetic testing is recommended for front-line treatment in OV, including BRCA1/2, HRD, PALB2, BARD1, etc. Studies have proved that higher mutational burden and PD-L1 expression in ovarian cancer are associated with BRCA mutations [36], which may make these cancers more suitable for ICB therapy [37]. This evidence concerns the gene TBCE and ovarian carcinoma.